PFIZER INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Therapy After Failure of Dual Oral Therapy.
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-08-31
- Last Posted Date
- 2007-02-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 345
- Registration Number
- NCT00370565
- Locations
- ๐จ๐ฆ
Pfizer Investigational Site, Laval, Quebec, Canada
Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity
Phase 2
Terminated
- Conditions
- Obesity
- First Posted Date
- 2006-08-23
- Last Posted Date
- 2011-08-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT00367783
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, San Antonio, Texas, United States
Azithromycin Plus Chloroquine Versus Mefloquine In the Treatment of Uncomplicated P. Falciparum Malaria.
- First Posted Date
- 2006-08-23
- Last Posted Date
- 2008-09-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 397
- Registration Number
- NCT00367653
- Locations
- ๐ฟ๐ฒ
Pfizer Investigational Site, Ndola, Zambia
A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-08-22
- Last Posted Date
- 2008-01-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00367445
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Chula Vista, California, United States
Zmax Compared to Augmentin in Sinusitis
Phase 4
Completed
- Conditions
- Sinusitis
- First Posted Date
- 2006-08-22
- Last Posted Date
- 2010-03-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 762
- Registration Number
- NCT00367120
A Pilot Methodology Study To Evaluate Changes In Bone Quality Parameters Following Therapy With Forteo
- First Posted Date
- 2006-08-18
- Last Posted Date
- 2009-03-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00365924
- Locations
- ๐ฆ๐ท
Pfizer Investigational Site, Capital Federal - Buenos Aires, Argentina
Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B
Phase 3
Completed
- Conditions
- Hemophilia B
- Interventions
- Drug: Recombinant Coagulation Factor IX (BeneFIX)
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2011-10-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 50
- Registration Number
- NCT00364182
- Locations
- ๐ช๐ธ
Pfizer Investigational Site, Sevilla, Spain
A Trial Of Azithromycin SR For The Treatment Of Acute Bronchitis And Secondary Infection Of Chronic Respiratory Diseases
Phase 3
Completed
- Conditions
- Acute Bronchitis
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2011-04-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 64
- Registration Number
- NCT00360464
- Locations
- ๐ฏ๐ต
Pfizer Investigational Site, Yonezawa, Yamagata, Japan
A Trial Of Azithromycin SR For The Treatment Of Mild To Moderate Community Acquired Pneumonia In Japanese Adults
Phase 3
Completed
- Conditions
- Pneumonia, Community-Acquired
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2008-05-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 153
- Registration Number
- NCT00360295
- Locations
- ๐ฏ๐ต
Pfizer Investigational Site, Yamagata, Japan
A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections
Phase 4
Completed
- Conditions
- Infection
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2008-12-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 307
- Registration Number
- NCT00360607
- Locations
- ๐ฎ๐ณ
Pfizer Investigational Site, Mumbai, India
ยฉ Copyright 2025. All Rights Reserved by MedPath